NEWS SUMMARY: IBERDROLA, SANTANDER. Lagarde admits progress made in inflation European stock markets saw profit taking, where J. Powell’s still cautious comments from Sintra but more confident in the disinflation process moderated losses. In the STOXX 600 among the sectors that rose (8/20 sectors), Energy stood out (thanks to the good performance of Brent crude) vs. Banks, Insurance and Autos that were the worst performers, falling >-1.0%. On the macro side, in the euro zone June’s inflation m...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, SANTANDER. EUROPA: SANOFI. Lagarde reconoce los progresos de la inflación Toma de beneficios en el mercado bursátil europeo donde los comentarios de J. Powell desde Sintra sonando todavía cauto, pero más confiado sobre el proceso de desinflación ayudaron a moderar las pérdidas. En el STOXX 600 entre los sectores que presentaron subidas (8/20 sectores) destacó Energía (gracias al buen desempeño del Brent) frente a Bancos, Seguros y Autos q...
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of lifeDupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU Approval ...
Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Première approbation au monde de Dupixent pour le traitement de la BPCO non contrôlée de l’adulte avec éosinophilie sanguine élevée, sur la base de deux études pivots de phase III ayant montré que Dupixent permet de réduire significativement les exacerbations de la maladie et d’améliorer la fonction respiratoire, ainsi que la qualité de vie en ...
>Outperform rating and € 14.40 target price maintained - The webinar organised by the group and dedicated to the network activities with the focus on the planning and supply of equipment and services, confirms our positive view on the stock, its strategic vision and capacity to achieve its targets. We maintain our Outperform rating and target price of € 14.4, based on the average between a DCF (€ 16.0) factoring in the targets of the 2026 strategic plan, a sum-of-the-...
>Opinion Surperformance et OC 14.40€ maintenus - Le webinar organisé par le groupe et dédié aux activités de réseau à travers le prisme de la planification et de l’approvisionnement en équipements et services confirme notre opinion positive sur le groupe, ses visions stratégiques et sa capacité à atteindre ses objectifs. Nous maintenons notre opinion Surperformance et notre objectif de cours de 14.4 €, issu d’une moyenne entre un DCF (16.0 €) intégrant les objectifs d...
A director at Sanofi bought 443 shares at 93.885USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has...
Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans La majorité des patients de cette tranche d’âge traités par Dupixent pour une œsophagite à éosinophiles ont présenté une rémission histologique et des améliorations soutenues pendant une durée pouvant aller jusqu’à un an.Dupixent est le premier et le ...
Press Release: Availability of the Q2 2024 Aide-mémoire Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's second-quarter 2024 results will be published on July 25, 2024. About SanofiWe...
Our conviction on the long-term growth potential and opportunities of generative AI is renewed. The enabler sectors (semiconductors, software and IT services) and those that provide the infrastructure (utilities, metals, capital goods and real estate) will be the primary beneficiaries, leading us to make certain target price changes. Among AI ‘user’ sectors (media, healthcare, automotive, banking and insurance, oil services, defence, aerospace and airlines), the effects will doub...
Notre conviction sur le potentiel de croissance LT et d’opportunités de l’IA générative est renforcée. Les secteurs 'enablers' (semiconducteurs, software et IT services) et fournisseurs d’infrastructures (utilities, métaux, biens d'équipements et immobilier) en seront les premiers bénéficiaires, conduisant à certains changements d’OC. Parmi les secteurs ‘utilisateurs’ de l’IA (média, santé, automobile, banque et assurance, services pétroliers, défense, aéronautique et compagnies ...
Peu de secteurs polarisent autant que le luxe automobile sportif. A la pointe de l’innovation technologique et artistique pour les uns, il est le reflet d’inégalités excessives pour les autres. Nous estimons que le secteur a un rôle prépondérant à jouer sur l’atténuation du changement climatique, mais aussi l’économie circulaire ou la transition juste. Considérant les impacts, risques et opportunités matériels, nous plaçons Ferrari en Best-in-Class ESG, Porsche en Neutre ESG, et Aston...
Few sectors are as polarising as luxury sports cars. At the cutting edge of technological and artistic innovation for some, they reflect excessive inequality for others. We believe the sector has a key role to play in climate change mitigation, as well as in the circular economy and just transition. Taking into account material impacts, risks and opportunities, we see Ferrari as ESG Best-in-Class, Porsche as ESG Neutral and Aston-Martin Lagonda as ESG Not Recommended. - ...
>Encouraging top-line data for a priority review as of H2 - Sanofi's share price gained more than 3% yesterday following the announcement of the positive top-line results of its partner Alnylam (+37%). The phase III study (HELIOS-B) evaluating vutrisiran (Amvuttra) in the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM), a rare life-threatening systemic disease. The study thus achieved its main endpoint of reducing the composite score of all causes of ...
>Des données topline encourageantes pour une revue prioritaire dès le S2 - Le cours de Sanofi a gagné plus de 3% hier à la suite de l’annonce des résultats topline, positifs, de son partenaire Alnylam (+37%), suite à l’étude de phase 3 (HELIOS-B) évaluant vutrisiran (Amvuttra) dans le traitement de la cardiomyopathie amyloïde à transthyrétine (ATTR-CM), une maladie systémique rare engageant le pronostic vital du patient. L’étude a ainsi atteint son principal crit...
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
Dutch real estate companies showed signs of cautious optimism at the recent Provada conference, with logistics and retail favoured. Healthcare shows some positive signs, with limited devaluations. The Dutch government's potential reduction of the Real Estate Transfer Tax and new REIT regime could benefit listed real estate companies active in the country. - ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.